SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending with strong bullish sentiment following recent significant revenue growth and Saudi FDA approval for its cancer treatment, with investors buzzing about Dr. Patrick Soon-Shiong's presentations and the potential for a massive short squeeze.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. TeraWulf will generate domestically produced bitcoin powered by nuclear, hydro and solar energy. The company was founded by Paul Prager and Nazar Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf is trending due to its strategic pivot from Bitcoin mining to a high-performance computing and AI data center provider, backed by significant power infrastructure acquisitions and bullish institutional coverage. The community is actively discussing its high short interest and long-term growth potential as an AI infrastructure play, amidst varying views on short-term price action.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

SanDisk is trending amidst a highly volatile session, fueled by Citron Research announcing a short position that challenges the strong demand narrative in the AI-driven memory and storage sector. The community is sharply divided between those betting on a short squeeze and those warning of overvaluation and a potential market correction.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is actively discussed as reports from peers like Samsung indicate surging HBM4 memory prices, strengthening the bullish conviction among the community regarding an accelerating AI-driven memory supercycle that is driving demand.

Zeta Global Holdings Corp. operates as a marketing technology software company, which engages in the provision of enterprises with consumer intelligence and marketing automation software. It enables its customers to target, connect and engage consumers through software that delivers marketing across all addressable channels, including email, social media, web chat, connected TV and video among others. The company was founded by David A. Steinberg and John Sculley on May 9, 2012 and is headquartered in New York, NY.

Zeta Global Holdings Corp - Ordinary Shares - Class A

Zeta Global Holdings Corp

Zeta Global is trending with notable pre-earnings strength, fueled by expectations of an 18th consecutive beat and raise and the continued integration of its OpenAI partnership into its AI marketing platform. Community sentiment is divided between strong bullish conviction in its proprietary data moat and concerns over broader software sector headwinds potentially leading to a "sell the news" event.

Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.

Vir Biotechnology Inc

Vir Biotechnology is trending following a significant strategic collaboration with Astellas for its VIR-5500 prostate cancer asset, bolstered by positive Phase 1 trial data and multiple analyst upgrades. The community is actively discussing the substantial financial commitment and the potential for a short squeeze, given the tight float and notable short interest.

Rich Sparkle Holdings Ltd. engages in the provision of financial printing and corporate services. The firm offers typesetting, proofreading, translation, design, and printing of listing documents, financial reports, fund documents, circulars, and announcements. It also delivers advisory services, such as conducting internal control assessment and environmental, social and governance performance evaluation, and other services including provision of co-working space. The company was founded in 2016 and is headquartered in Hong Kong.

Rich Sparkle Holdings Ltd.

Rich Sparkle Holdings Limited

Rich Sparkle Holdings Limited (ANPA) is trending due to its acquisition of TikTok icon Khaby Lame's core company, sparking community excitement about potential explosive growth in digital content. However, the move is also drawing significant skepticism and warnings of a pump-and-dump, with many questioning its valuation compared to fundamentals.

Cipher Mining, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Mining Inc

Cipher Mining, now Cipher Digital, is drawing significant attention after its earnings call underscored a successful pivot to AI/HPC data centers, showcasing on-schedule builds and an expanding pipeline of hyperscaler deals, which overshadows its Q4 financial miss. The community is actively discussing the strategic re-rating potential, driven by confirmed multi-billion dollar contracts and anticipation of new "imminent" agreements.

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

Ardelyx is trending as a key director's substantial insider purchase and a new LPGA marketing partnership signal strong long-term confidence, even while the community debates its undervalued status, the impact of increased growth-oriented expenses, and ongoing buyout speculation.

Workday, Inc. engages in the provision of development of enterprise cloud applications for finance and human resources. It delivers financial management, human capital management and analytics applications designed for companies, educational institutions, and government agencies. The company was founded by David A. Duffield and Aneel Bhusri in 2005 and is headquartered in Pleasanton, CA.

Workday Inc - Ordinary Shares - Class A

Workday Inc

Workday is experiencing a sharp sell-off post-earnings, as cautious subscription revenue guidance amplifies broader investor concerns about AI disruption in the SaaS sector, leading to a polarized community debate over its valuation and future prospects.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

DiaMedica Therapeutics to Participate in Upcoming March Investor Conferences

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke...

DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Shares of DiaMedica Therapeutics, Inc. (NASDAQ:DMAC - Get Free Report) have received a consensus rating of "Moderate Buy" from the six research firms that are currently covering the firm, MarketBeat...

Short Interest in DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Declines By 22.8%

DiaMedica Therapeutics, Inc. (NASDAQ:DMAC - Get Free Report) was the recipient of a significant decline in short interest in the month of December. As of December 31st, there was short interest...

DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Receives Consensus Rating of "Moderate Buy" from Brokerages

DiaMedica Therapeutics, Inc. (NASDAQ:DMAC - Get Free Report) has earned an average recommendation of "Moderate Buy" from the seven brokerages that are covering the company, MarketBeat.com reports...

DiaMedica Therapeutics, Inc. (NASDAQ:DMAC - Get Free Report) has been assigned an average rating of "Moderate Buy" from the seven ratings firms that are currently covering the firm, Marketbeat...

DiaMedica Therapeutics (NASDAQ:DMAC) Trading Up 7.4% - Here's Why

DiaMedica Therapeutics (NASDAQ:DMAC) Shares Up 7.4% - Here's Why...

DiaMedica Therapeutics (NASDAQ:DMAC) Sets New 1-Year High - Time to Buy?

DiaMedica Therapeutics (NASDAQ:DMAC) Hits New 1-Year High - Here's What Happened...

Jan Stahlberg Buys 128,426 Shares of DiaMedica Therapeutics (NASDAQ:DMAC) Stock

DiaMedica Therapeutics, Inc. (NASDAQ:DMAC - Get Free Report) major shareholder Jan Stahlberg acquired 128,426 shares of the business's stock in a transaction that occurred on Thursday, November 20th...

Jan Stahlberg Acquires 240,352 Shares of DiaMedica Therapeutics (NASDAQ:DMAC) Stock

DiaMedica Therapeutics, Inc. (NASDAQ:DMAC - Get Free Report) major shareholder Jan Stahlberg bought 240,352 shares of the firm's stock in a transaction on Wednesday, November 19th. The stock was...

DiaMedica Therapeutics, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of novel recombinant proteins. It develops the DM199 product candidate, which focuses on acute ischemic stroke (AIS) and chronic kidney disease (CKD). The company was founded by Wayne Lautt on January 21, 2000 and is headquartered in Minneapolis, MN.

DiaMedica Therapeutics Inc

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

Ahead of earnings, sentiment is split between blowout AI growth and concerns around macro pressure, positioning, and post-ER volatility. How do you see it playing out?

Current Price	$8.44
Prev Close	$8.31
Open	$8.48
Dividend Yield	0.00%
50-Day Moving Average	$8.37
Beta	1.20
Avg. Volume	251,500.85
PE Ratio	-11.59

52-Week High	$10.42
52-Week Low	$3.19
Market Capitalization	$432.76M
EPS (Annual)	-$0.605
Price to Book	8.38
Revenue Per Employee	$0.00

DMAC
DiaMedica Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest DMAC News

DMACDiaMedica Therapeutics Inc